Emerald green DNA double helix on a dark teal background

FDA Rejects Capricor’s Deramiocel Over HOPE-3 Data Integrity

Table of Contents

FDA rejected Capricor’s deramiocel for Duchenne on Nov 20, 2026, citing data integrity violations in HOPE-3. What the CRL says and what it means for sponsors.

Last updated: November 21, 2026

The FDA issued a second complete response letter for Capricor Therapeutics’ deramiocel in Duchenne muscular dystrophy on November 20, 2026, two days before its action date. The agency says its inspection found unauthorized changes to the HOPE-3 statistical analysis plan and blinding violations that cannot be fixed after the fact.

Scope: what the FDA and Capricor each said, how the application got here, and what the decision tells sponsors running pivotal trials in rare disease.

What did the FDA say about deramiocel?

The FDA said the evidence “does not meet the evidentiary standard required for approval” and that the problem is the reliability of the pivotal data itself, not just the size of the effect. That is an unusual thing for the agency to say in public about a sponsor’s Phase 3 trial.

In a statement posted November 20, 2026 by the Center for Biologics Evaluation and Research, the FDA said its correspondence “identifies serious data integrity violations in the conduct of Study HOPE-3,” violations it says cannot be fixed after the fact. It listed them: “unauthorized post hoc changes to the statistical analysis plan; violations of study blinding procedures; and additional protocol violations that, individually and collectively, compromise the reliability of the study data.”

The findings came from the agency’s Bioresearch Monitoring (BIMO) program, which inspected Capricor in connection with the application. The FDA also issued a separate Regulatory Responsibility Letter dated November 20, 2026, and said Capricor “will have the opportunity to address the issues” in it. The statement closes with a line every clinical operations head will quote this week: “the agency cannot approve a product on the basis of data whose reliability has been compromised.”

The FDA also noted that Capricor “changed its proposed indication to seek approval for treatment of upper limb impairment rather than treatment of cardiomyopathy in DMD.”

What did Capricor say?

Capricor confirmed the complete response letter but did not repeat the FDA’s integrity findings. Its release, timed 7:55 pm ET on November 20, says the letter states the FDA “does not consider the data sufficient to establish substantial evidence of effectiveness” and “cites certain other clinical deficiencies.”

Chief executive Linda Marbán said deramiocel “has been studied in two randomized, double blind, placebo controlled trials, HOPE-2 and HOPE-3,” and that “both of which met their primary endpoints.” She added: “We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval.” The company said it is reviewing the letter and will share next steps after that review. A conference call is set for Monday, November 23, at 8:30 am ET.

Order matters here. The FDA statement and a Reuters report were public before Capricor’s release, so investors read the agency’s version first. Capricor’s release does not use the words “statistical analysis plan” or “blinding.”

How did the deramiocel application get here?

This is the second rejection in 16 months, and the target moved along the way: the first application sought a cardiomyopathy label, and the final one sought an upper limb function claim.

Date Event Source
July 11, 2025 Capricor discloses first CRL for the cardiomyopathy BLA; FDA says the application does not meet the statutory standard for substantial evidence of effectiveness Capricor 8-K exhibit
Dec 3, 2025 HOPE-3 topline: 106 randomized at 20 US sites; PUL v2.0 slowing of 54% vs placebo (p=0.029, n=105); LVEF slowing of 91% (p=0.041, n=83) Capricor 8-K exhibit
Mar 10, 2026 Resubmission classified as Class 2; action date set for Aug 22, 2026 Capricor release
July 29, 2026 Cellular, Tissue and Gene Therapies Advisory Committee votes 9 against, 3 for on effectiveness in DMD cardiomyopathy FDA briefing slides (question); Capricor release (count)
Aug 24, 2026 FDA classifies new data as a major amendment; action date moves to Nov 22, 2026; refined indication focused on upper limb function Capricor release
Nov 20, 2026 Second CRL plus Regulatory Responsibility Letter, two days before the action date FDA statement; Capricor release

The advisory committee question, from the FDA’s own slides, was: “Does the available evidence provide substantial evidence of effectiveness of deramiocel for the treatment of cardiomyopathy in patients with DMD?” Capricor argued at the time that the question “addressed a narrower indication than Capricor had proposed.” NeurologyLive reported that FDA reviewers at that meeting questioned revisions to the statistical analysis plan, including the timing of the final version relative to database lock, which Capricor disputed. The November statement shows the inspection turned those concerns into formal findings.

What is deramiocel?

Deramiocel is an allogeneic cell therapy made of cardiosphere derived cells, given by intravenous infusion. In HOPE-3 it was dosed at 150 million cells every three months for 12 months. It holds Orphan Drug, Regenerative Medicine Advanced Therapy and Rare Pediatric Disease designations in the US, per Capricor.

Nippon Shinyaku is named in a 2022 agreement as exclusive US distributor for deramiocel in DMD, per Capricor’s third quarter 10-Q. The same filing shows the two companies are now in a dispute: Capricor sued in May 2026 seeking rescission, and the matter has moved to arbitration with claims on both sides.

Why does a data integrity finding matter more than a weak effect?

A borderline effect can be fixed with more patients. A finding that the pivotal trial’s analysis plan and blinding were compromised can only be fixed with a new trial, because the existing data cannot be reanalyzed into reliability.

That is the practical meaning of the FDA’s point that the problems cannot be fixed after the fact. Reanalysis under an earlier version of the plan does not help if the agency does not trust how the plan evolved. Longer open label follow up does not help either, since the open label phase cannot answer a blinding question about the randomized phase. For a company with about $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, which Capricor says funds planned operations for at least 12 months, that changes the math on any path that runs through another randomized study.

CRL type Typical fix Where deramiocel sits
Manufacturing or CMC deficiencies Facility or process remediation, then resubmission Part of the 2025 letter (six CMC items per Capricor’s briefing book)
Effect too small or endpoint not persuasive Additional analyses, longer follow up, or a confirmatory trial The 2025 letter and the 9 to 3 committee vote
Data reliability compromised Respond to inspection findings; usually a new adequate and well controlled trial The 2026 letter, per the FDA statement

The middle column is our framework reading of typical outcomes, not an FDA rule. For the formal mechanics of responding, see our complete response letter explainer.

What does this mean for the Duchenne field?

Families lose a candidate that targeted both skeletal and cardiac decline, and the treatment shelf stays thin. Italfarmaco’s Duvyzat (givinostat) was approved on March 21, 2024 for patients six years and older. On November 14, 2025 the FDA added a boxed warning for serious liver injury and acute liver failure to Sarepta’s Elevidys and limited its use to ambulatory patients four years and older.

For other DMD developers, the read is less about the disease and more about trial conduct. The FDA has shown repeated flexibility in rare disease on endpoints and on single trial packages. This decision says that flexibility does not extend to how the trial was run.

Checklist: protecting a pivotal trial from an integrity finding (our framework)

  • Finalize the statistical analysis plan before any unblinded data exists, and keep a dated, version controlled record of every amendment and who approved it.
  • If an amendment is unavoidable late in a study, document that the people writing it had no access to unblinded results, and tell the FDA before lock.
  • Firewall the unblinded statistics team from the sponsor’s clinical and executive teams, with written access logs.
  • Watch for safety signals that could reveal treatment assignment, such as infusion reactions concentrated in one arm, and plan how assessors stay blind if that happens.
  • Run a mock BIMO inspection on the pivotal study before filing, not after the advisory committee.
  • Keep the primary endpoint and indication aligned with what the pivotal trial was designed to show; a late indication change invites a closer look at how the analysis evolved.

What to watch next

  • Monday, November 23, 8:30 am ET: Capricor’s call, the first chance to hear its response to the integrity findings and any plan for the Regulatory Responsibility Letter.
  • Monday is also the first regular trading session after the decision, since both releases crossed after Friday’s close.
  • Whether the FDA publishes the full CRL text, as it did for the July 2025 letter according to Fierce Biotech.
  • The Nippon Shinyaku arbitration and whether the distribution deal survives.
  • Cost actions: Capricor says it is reviewing operating costs to extend its runway.

Frequently asked questions

Did the FDA approve deramiocel?

No. The FDA issued a complete response letter on November 20, 2026, the second for the deramiocel application in Duchenne muscular dystrophy.

Why did the FDA reject deramiocel?

The FDA said its inspection found unauthorized post hoc changes to the HOPE-3 statistical analysis plan, blinding violations and other protocol violations that compromise the reliability of the data, and that the evidence does not meet the approval standard.

Did Capricor acknowledge the data integrity findings?

Capricor’s release says the letter cites insufficient evidence of effectiveness and “certain other clinical deficiencies.” It does not repeat the FDA’s integrity language, and the CEO said the company stands behind the integrity of its data.

What is a Regulatory Responsibility Letter?

The FDA said it issued one on November 20, 2026 in connection with the BIMO inspection observations, and that Capricor will have the opportunity to address the issues in it. It is separate from the complete response letter.

What was the PDUFA date for deramiocel?

November 22, 2026, after the FDA classified new data as a major amendment in August and moved the date from August 22. The decision came two days early.

What indication was Capricor seeking?

The original application sought treatment of DMD cardiomyopathy. Per the FDA, Capricor changed the proposed indication to upper limb impairment.

What did HOPE-3 show?

Capricor reported in December 2025 that HOPE-3 randomized 106 participants and showed a 54% slowing of decline on the PUL v2.0 upper limb scale (p=0.029) and 91% slowing on LVEF (p=0.041). The FDA now says those data are not reliable.

How did the advisory committee vote?

On July 29, 2026 the committee voted 9 against and 3 for on whether the evidence showed effectiveness in DMD cardiomyopathy, per Capricor’s release on the meeting.

How much cash does Capricor have?

About $198.5 million as of September 30, 2026, which the company says is enough for at least 12 months of planned operations.

What DMD treatments are FDA approved?

Approved options include Duvyzat (givinostat, approved March 2024 for patients six and older) and Elevidys, which since November 2025 carries a boxed liver warning and is limited to ambulatory patients four years and older.

Sources

  • FDA, Statement on deramiocel BLA for Duchenne muscular dystrophy, Nov 20, 2026 (primary): https://www.fda.gov/vaccines-blood-biologics/whats-new-biologics/statement-deramiocel-bla-duchenne-muscular-dystrophy
  • Capricor, Regulatory update on deramiocel BLA, Nov 20, 2026 (primary): https://www.globenewswire.com/news-release/2026/11/21/3407877/0/en/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-for-duchenne-muscular-dystrophy.html
  • Capricor 10-Q for the quarter ended Sept 30, 2026 (primary): https://www.sec.gov/Archives/edgar/data/0001133869/000110465926125355/capr-20260930x10q.htm
  • Capricor, HOPE-3 topline, Dec 3, 2025, 8-K exhibit (primary): https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-25-117947/capr-20251203xex99d1.htm
  • Capricor, first CRL release, July 11, 2025, 8-K exhibit (primary): https://www.sec.gov/Archives/edgar/data/0001133869/000155837025009186/capr-20250711xex99d1.htm
  • Capricor, Class 2 resubmission and new PDUFA date, Mar 10, 2026 (primary): https://www.biospace.com/press-releases/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla
  • FDA briefing slides, CTGTAC July 29, 2026 (primary): https://www.fda.gov/media/193912/download
  • Capricor, advisory committee update, July 30, 2026 (primary): https://www.biospace.com/press-releases/capricor-therapeutics-provides-update-on-fda-advisory-committee-meeting-for-deramiocel
  • Capricor, PDUFA extension, Aug 24, 2026 (primary): https://finviz.com/news/384886/capricor-therapeutics-announces-extension-of-pdufa-target-action-date-as-fda-continues-review-of-deramiocel-bla
  • FDA, Duvyzat approval, Mar 21, 2024 (primary): https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy
  • FDA, Elevidys safety warning and revised indication, Nov 14, 2025 (primary): https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal
  • Reuters via WTVB, Nov 20, 2026 (attributed): https://wtvbam.com/2026/11/20/us-fda-declines-to-approve-capricors-cell-therapy-for-duchenne-muscular-dystrophy-shares-slump/
  • NeurologyLive, advisory committee coverage (attributed): https://www.neurologylive.com/view/fda-advisory-committee-votes-against-deramiocel-dmd-cardiomyopathy
  • Fierce Biotech, FDA release of the 2025 CRL (attributed): https://www.fiercebiotech.com/biotech/capricor-shares-response-cell-therapy-denial-after-fda-publicly-releases-rejection-letter

Related coverage

Get the daily briefing on what moved in biotech, pharma and medtech: subscribe to BioMed Nexus.

Featured Articles

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters